........."These data provide a detailed justification for the clinical development for
iPPS with the dosing regimen of 2 mg/kg twice weekly for 6 weeks of initial therapy."
.......
"The key items addressed in the Type D response submission to the FDA include:
• The minimal effective dose justification.
• Additional nonclinical studies completed to GLP standards to address previously
noted adrenal findings.
• Draft clinical trial protocol.
• Revised safety monitoring and mitigation plan.
Subject to FDA clearance, Paradigm intends to promptly move forward with subject
enrolment into the phase 3 clinical trial (PARA_OA_012) in 2H CY2024......"
2 mg/kg has never been cleared by the FDA. If it was, you can bet your bottom dollar that 2 mg/kg would have been in the dosing study to generate comparable data. Even you would do that.
BTW - you don't submit a new IND, on top of an IND for the same investigation...
MPS trial - failed with no hope of a partner.
Dosing study for OA - failed or as Donna Skerett put it "Did not meet the required performance thresehold"
- Forums
- ASX - By Stock
- Where we at?
........."These data provide a detailed justification for the...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M |
Open | High | Low | Value | Volume |
20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 387930 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 65468 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 384246 | 0.190 |
3 | 57000 | 0.185 |
8 | 194873 | 0.180 |
6 | 140904 | 0.175 |
7 | 595605 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 65468 | 2 |
0.210 | 25992 | 3 |
0.215 | 30000 | 1 |
0.220 | 27066 | 4 |
0.225 | 21604 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |